International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 205-214
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Potential of Protein Expression Profiles in Categorization Risks for Acute Myeloid Leukemia: A Pilot Study
Amer ALMAIMAN1,2, Rasedee ABDULLAH1, Ahmad B. bin ABDUL1, Zeenathul N. ALLAUDDIN1, Ayodele A. ALAIYA2, Eltayeb EM. EID3, Zakia SHINWARI2, Ghada Al JUHANI4, Walid RASHEED4, Nasir BAKSHI5, Tareq OWAIDAH5, Syed O. AHMED2, Mahmoud ALJURF4
1Universiti Putra Malaysia, Institute of Bioscience, Malaysia
2King Faisal Specialist Hospital and Research Center, Proteomics Unit Stem Cells & Tissue Re-Engineering Program, Riyadh, Saudi Arabia
3Qassim University, Uniazah College of Pharmacy, Qassim, Saudi Arabia
4King Faisal Specialist Hospital and Research Center, Oncology Center, Riyadh, Saudi Arabia
5King Faisal Specialist Hospital and Research Center, Department of Pathology and Laboratory Medicine, Riyadh, Saudi Arabia
Keywords: Acute Myeloid Leukemia, Proteomics, Risk category, Biomarker discovery
Currently, there are no markers to predict response to acute myeloid leukemia (AML) therapy and patients have to wait for a period of 3-6 months to see treatment response. The study aimed to analyze changes in protein expression in AML cells between different categorization risk groups using proteomics techniques. Six peripheral blood (PB) and six bone marrow (BM) samples at diagnosis and remission times were collected from AML patients. Another Six PB samples were collected from different categories of AML. All samples were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). The levels of proteins in patients with AML were compared at different categorization risk, individual response to treatment and clinical characteristics. Twenty-one and 145 differentially expressed proteins were identified with disease progression and risk categories of AML, respectively. Three (3) proteins were noticeably highly expressed out of the range of others proteins by at least 3- fold difference between diagnosis and remission. Two other of proteins were up regulated by more than 10 folds between risk categories of AML. Furthermore, 4 proteins were found to be expressed in one risk category, but were not detectable in other two risk categories. The study showed that a panel of differentially expressed protein profiles might serve as more objective biomarkers for accurate stratification of different risk categories of AML.
Amer ALMAIMAN1,2, Rasedee ABDULLAH1, Ahmad B. bin ABDUL1, Zeenathul N. ALLAUDDIN1, Ayodele A. ALAIYA2, Eltayeb EM. EID3, Zakia SHINWARI2, Ghada Al JUHANI4, Walid RASHEED4, Nasir BAKSHI5, Tareq OWAIDAH5, Syed O. AHMED2, Mahmoud ALJURF4
1Universiti Putra Malaysia, Institute of Bioscience, Malaysia
2King Faisal Specialist Hospital and Research Center, Proteomics Unit Stem Cells & Tissue Re-Engineering Program, Riyadh, Saudi Arabia
3Qassim University, Uniazah College of Pharmacy, Qassim, Saudi Arabia
4King Faisal Specialist Hospital and Research Center, Oncology Center, Riyadh, Saudi Arabia
5King Faisal Specialist Hospital and Research Center, Department of Pathology and Laboratory Medicine, Riyadh, Saudi Arabia
Keywords: Acute Myeloid Leukemia, Proteomics, Risk category, Biomarker discovery
Currently, there are no markers to predict response to acute myeloid leukemia (AML) therapy and patients have to wait for a period of 3-6 months to see treatment response. The study aimed to analyze changes in protein expression in AML cells between different categorization risk groups using proteomics techniques. Six peripheral blood (PB) and six bone marrow (BM) samples at diagnosis and remission times were collected from AML patients. Another Six PB samples were collected from different categories of AML. All samples were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). The levels of proteins in patients with AML were compared at different categorization risk, individual response to treatment and clinical characteristics. Twenty-one and 145 differentially expressed proteins were identified with disease progression and risk categories of AML, respectively. Three (3) proteins were noticeably highly expressed out of the range of others proteins by at least 3- fold difference between diagnosis and remission. Two other of proteins were up regulated by more than 10 folds between risk categories of AML. Furthermore, 4 proteins were found to be expressed in one risk category, but were not detectable in other two risk categories. The study showed that a panel of differentially expressed protein profiles might serve as more objective biomarkers for accurate stratification of different risk categories of AML.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |